Document Detail


Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival.
MedLine Citation:
PMID:  11250039     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
High-dose intravenous immunoglobulin (IVIg) is used as therapy in an increasing number of immune mediated disorders including infections and autoimmune conditions. IVIg exerts profound effects both in vivo as well as in vitro on humoral and cell-mediated immunity. In this study we investigated whether IVIg could alter the pattern of apoptosis and apoptosis related proteins including Bcl-2, Bax, p53, CD95, and p21/WAF-1, a protein well known to arrest cells in G1 phase of the cell cycle and finally proliferation marker Ki-67 on peripheral blood mononuclear cells (PBMC). The cells were cultured either unstimulated or with mitogen in the presence or absence of different IVIg preparations. A dual effect by IVIg was found. The incidence of apoptosis was elevated in activated Ki-67 and CD95 positive PBMC, whereas it was lower in small, nonactivated cells. The cells that survived were associated with a striking increase in the expression of p21/WAF-1 suggesting G1 arrest. A concomitant upregulation of Bcl-2 was also obtained by IVIg exposition resulting in long-term survival. We suggest that these abilities of IVIg to alter cell cycle progression and apoptosis could explain some of the beneficial effects obtained in vivo with IVIg therapy.
Authors:
C Ekberg; E Nordström; U Skansén-Saphir; M Mansouri; R Raqib; V A Sundqvist; C Fernàndez
Related Documents :
11454049 - Two relatively distinct patterns of ameloblastoma: an anti-apoptotic proliferating site...
10362019 - Activation of the camp signaling pathway increases apoptosis in human b-precursor cells...
15377529 - Bcl-xl-dependent light scattering by apoptotic cells.
18687309 - Inhibition of receptor-mediated apoptosis upon bcl-2 overexpression is not associated w...
20139069 - Fkbp38 protects bcl-2 from caspase-dependent degradation.
19533419 - Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligo...
11408569 - Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation.
10194839 - Killed whole bacterial cells, a mucosal delivery system for the induction of immunity i...
11859129 - Il-10 is critical for host resistance and survival during gastrointestinal helminth inf...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Human immunology     Volume:  62     ISSN:  0198-8859     ISO Abbreviation:  Hum. Immunol.     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-16     Completed Date:  2001-05-31     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  8010936     Medline TA:  Hum Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  215-27     Citation Subset:  IM    
Affiliation:
Department of Immunology, the Wenner-Gren Institute, Stockholm University, Stockholm, Sweden. carolineekberg@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibody Specificity / immunology*
Apoptosis
Azure Stains
Cell Division
Cyclin-Dependent Kinase Inhibitor p21
Cyclins / biosynthesis,  physiology*
G1 Phase
Humans
Immunoglobulins, Intravenous / immunology*,  therapeutic use
In Situ Nick-End Labeling / methods
Leukocytes, Mononuclear / cytology
Lymphocyte Activation
Proto-Oncogene Proteins c-bcl-2 / biosynthesis,  physiology*
Time Factors
Chemical
Reg. No./Substance:
0/Azure Stains; 0/CDKN1A protein, human; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Cyclins; 0/Immunoglobulins, Intravenous; 0/Proto-Oncogene Proteins c-bcl-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in dendritic cell subsets in the lymph nodes of rhesus macaques after application of glucoco...
Next Document:  Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. E...